- Home
- DBVT vs MVT Comparison
DBVT vs MVT Comparison
Compare DBVT & MVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- MVT
- Stock Information
- Founded
- DBVT 2002
- MVT 1993
- Country
- DBVT France
- MVT United States
- Employees
- DBVT N/A
- MVT N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- MVT Investment Bankers/Brokers/Service
- Sector
- DBVT Health Care
- MVT Finance
- Exchange
- DBVT Nasdaq
- MVT Nasdaq
- Market Cap
- DBVT 239.9M
- MVT 214.7M
- IPO Year
- DBVT N/A
- MVT N/A
- Fundamental
- Price
- DBVT $8.01
- MVT $10.05
- Analyst Decision
- DBVT Buy
- MVT
- Analyst Count
- DBVT 4
- MVT 0
- Target Price
- DBVT $14.81
- MVT N/A
- AVG Volume (30 Days)
- DBVT 102.2K
- MVT 49.7K
- Earning Date
- DBVT 07-29-2025
- MVT 01-01-0001
- Dividend Yield
- DBVT N/A
- MVT 4.15%
- EPS Growth
- DBVT N/A
- MVT N/A
- EPS
- DBVT N/A
- MVT N/A
- Revenue
- DBVT $3,497,000.00
- MVT N/A
- Revenue This Year
- DBVT $1,700.53
- MVT N/A
- Revenue Next Year
- DBVT $535.67
- MVT N/A
- P/E Ratio
- DBVT N/A
- MVT N/A
- Revenue Growth
- DBVT N/A
- MVT N/A
- 52 Week Low
- DBVT $2.21
- MVT $8.96
- 52 Week High
- DBVT $12.78
- MVT $11.17
- Technical
- Relative Strength Index (RSI)
- DBVT 41.18
- MVT 42.99
- Support Level
- DBVT $8.33
- MVT $10.07
- Resistance Level
- DBVT $9.92
- MVT $10.20
- Average True Range (ATR)
- DBVT 0.86
- MVT 0.12
- MACD
- DBVT -0.34
- MVT -0.01
- Stochastic Oscillator
- DBVT 1.48
- MVT 22.50
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About MVT Blackrock MuniVest Fund II Inc.
Blackrock Munivest Fund II Inc is a closed-end management investment company. The fund's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Health, Utilities, Education, Housing, and other sectors.